Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus, Rituximab, and Bortezomib in Waldenstrom's Macroglobulinemia
NCT01125293Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2010
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in Waldenstrom macroglobulinemia (WM), sponsored by Dana-Farber Cancer Institute. Started Apr 2010; status: terminated.
02
Drugs
everolimus
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01125293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01125293.